Recent advances in nanoneurology for drug delivery to the brain

Current Nanoscience

Volumn 5, Issue 4, 2009, Pages 441-448

  Kanwar, Jagat R ^a   Mahidhara, Ganesh ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Blood brain barrier; Nanoneurology; Neurodegenerative diseases; Polymeric nanoparticles and multiple sclerosis

Indexed keywords

ADVANCED TECHNOLOGY; AMPHIPHILICS; BEST CHOICE; BLOOD-BRAIN BARRIER; CHEMICAL STRUCTURE; CONTROLLED RELEASE; DRUG DEVELOPMENT; ENDOTHELIAL SYSTEMS; LIPID NANOPARTICLES; MICRO-VASCULATURE; NANOCARRIERS; NANOMATERIAL; NANONEUROLOGY; NEURODEGENERATIVE DISEASES; NEURODEGENERATIVE DISORDERS; ORAL DELIVERY; POLYMERIC NANOPARTICLES AND MULTIPLE SCLEROSIS; POLYSORBATES; POTENTIAL APPLICATIONS; SPECIALIZED CELLS; SURFACE MODIFICATION; TROJAN HORSE; VASCULATURE;

BLOOD; DRUG DELIVERY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; SURFACE ACTIVE AGENTS;

POLYMERS;

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALGINIC ACID; ALPHA4 INTEGRIN ANTIBODY; ALPHA4BETA7 INTEGRIN ANTIBODY; CHITOSAN; COUMARIN; DEXTRIN; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLOXURIDINE 3',5' DIOCTANOATE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPOSOME; LOPERAMIDE; MACROGOL; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1 ANTIBODY; NANOMATERIAL; NITRENDIPINE; POLYGLACTIN; POLYLYSINE; POLYMER; POLYSORBATE; PROGESTERONE; SOLID LIPID NANOPARTICLE; TACRINE; TRIPALMITIN; TRISTEARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN MICROCIRCULATION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DEGENERATIVE DISEASE; DEPRESSION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; EPILEPSY; HUMAN; HUNTINGTON CHOREA; LIPOSOMAL GENE DELIVERY SYSTEM; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MULTIPLE SCLEROSIS; NANOTECHNOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; STROKE; SUSPENSION;

EQUIDAE;

EID: 70350761693     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341309789378014     Document Type: Review

References (76)

1. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharm. Ther., 2008, 5(83), 761-769.
2. Nishiyama, N. Nanocarriers shape up for long life. Nat. Nanotechnol., 2007, 2, 203-204.
3. Pardridge, W. M. Blood brain barrier drug targeting: the future of brain drug development. Mol. Interv., 2003, 3, 90-105.
4. Torchilin, V.P. Multi functional nanocarriers. Adv. Drug Deliv. Rev., 2006, 58, 1532-1555.
5. Kermani, F. CNS drugs and CNS markets: a strategic guide to CNS disorders, markets and therapies, 1999. http://www. europeanpharmaceutical.com
6. Pardridge, W.M. Brain drug targeting: the future of brain drug development. Cambridge University Press: Cambridge, 2001.
7. Ehrlich, P. Das Sauerstoff-Bedurfnis des Organismus: Eine Farbenanalytische Studie. Berlin: Hirschwald, 1885.
8. Pardridge, W.M. Blood-brain barrier: interface between internal medicine and the brain. Ann. Intern. Med., 1986, 105, 82-95.
9. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7, 41-53.
10. Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 57, 173-185.
11. Pardridge W.M. Molecular biology of the blood-brain barrier. Mol. Biotechnol., 2005, 30, 57-69.
12. Baratchi, S.; Kanwar, R.K.; Khoshmanesh, K.; Vasu, P.; Chauhan, A.; Hittu, M.; Andrew, P.; Krishnakumar, S.; Sun, X.; Sahoo, S.K.: Kanwar, J.R. Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Curr. Nanosci., 2009, 5(1), 15-25.
13. Kanwar, J.R. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr. Med. Chem., 2005, 12(25), 2947-2962. (Pubitemid 41672485)
14. Kanwar, J. R.; Harrison, J.E.B.; Wang, D.M.; Leung, E.; Mueller, W.; Wagner, N.; Krissansen, G.W. Beta 7 integrins contribute to demyelinating disease of the central nervous system. J. Neuroimmunol., 2000, 103(2), 146-152. (Pubitemid 30079726)
15. Kanwar, J.R.; Kanwar, R.K.; Wang, D. M.; Krissansen, G.W. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitisby an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol. Cell Biol., 2000, 78(6), 641-645.
16. Kanwar, J.R.; Kanwar, R.K.; Krissansen, G.W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain, 2004, 127(6), 1313-1331.
17. Tubridy, N.; Behan, P.O.; Capildeo, R.; Chaudhuri, A.; Forbes, R.; Hawkins, C.P. The effect of anti-alpha4 integrin antibody on brain lesion activity in multiple sclerosis. The UK Antegren Study Group. Neurology, 1999, 53, 466-472.
18. Krissansen, G.W.; Singh, J.; Kanwar, R.K.; Chan, Y.C.; Leung, E.; Lehnert, K.B.; Kanwar, J.R.; Yang, Y. A pseudosymmetric cell adhesion regulatory domain in the beta7 tail of the integrin alpha4beta7 that interacts with focal adhesion kinase and src. Eur. J. Immunol., 2006, 36(8), 2203-2214. (Pubitemid 44251765)
19. Pardridge, W.M. Drug Targeting to the Brain. Pharm. Res., 2007, 24(9), 1733-1744.
20. Pardridge, W.M. Re-engineering protein pharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem., 2008, 19, 1327-1338.
21. Pardridge, W.M. The blood brain barrier delivery. Drug. Discov. Today, 2007, 12, 54-61.
22. Nutt, J.G. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 2003, 60, 69-73. (Pubitemid 36070646)
23. Fung, L.K. Chemotherapeutic drugs released from polymers:Distribution of 1, 3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res., 1996, 13, 671-682.
24. Ai, Y. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol., 2003, 461, 250-261. (Pubitemid 36583466)
25. Anand Kumar, T.C.; David, G.F.; Sankaranarayanan, A.; Puri, V.; Sundram, K.R. Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying. Proc. Natl. Acad. Sci. USA, 1982, 79, 4185-4189.
26. Merkus, P.; Guchelaar, H.J.; Bosch, D.A.; F.W. Merkus, D.A. Direct access of drugs to the human brain after intranasal drug administration? Neurology, 2003, 60, 1669-1671.
27. Nadal, A. Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proc. Natl. Acad. Sci. USA, 1995, 92, 1426-1430.
28. Lossinsky, A.S. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. Neurocytology, 1995, 24, 795-806.
29. Salahuddin, T.S. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol., (Berl.), 1988 , 77, 5-13. (Pubitemid 19002265)
30. Lee, H.J.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through the blood-brain barrier in the mouse. J. Pharmacol. Exp. Ther., 2000, 292, 1048-1052.
31. Coloma, M.J.; Lee, H.J.; Kurihara, A.; Landaw, E.M.; Boado, R.J.; Morrison, S.L.; Pardridge, W.M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res., 2000, 17(3), 266-274.
32. Wu, D.; Pardridge, W.M. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther., 1996, 279, 77-83.
33. Zhang, Y.; Pardridge, W.M. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke, 2001, 32, 1378-1384.
34. Song, B.W. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther., 2002, 301, 605-610.
35. Lee, H.J. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J. Cereb. Blood Flow Metab., 2002, 22, 223-231.
36. Bodor, N. In: Biological Approaches to the controlled delivery of drugs. New York Academy of Sciences: New York, 1987, pp. 289-306.
37. Polt, R.; Porreca, F.; Szabo, L.Z.; Bilsky, E.J.; Davis, P.; Abbruscato, T.J.; Davis, T.P.; Harvath, R.; Yamamura, H.I.; Hruby, V.J. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. USA, 1994, 91, 7114-7118.
38. Palian, M.M.; Boguslavsky, V.I.; O'Brien, D.F.; Polt, R. Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. J. Am. Chem. Soc., 2003, 125, 5823-5831. (Pubitemid 36592908)
39. Egleton, R.D.; Mitchell, S.A.; Huber, J.D.; Janders, J.; Stropova, D.; Polt, R.; Yamamura, H.I.; Hruby, V.J.; Davis, T.P. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res., 2000, 881, 37-46.
40. Chrai. SS.; Murari, R.; Ahmad, I. Liposomes (a review), part one: manufacturing issues. BioPharm., 2001, 14(11), 10-14.
41. Allen, D.D.; Geldenhuys, W.J. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci., 2006, 78(10), 1029-1033
42. Shi, N.; Zhang, Y.; Zhu, C.; Boado, R.J.; Pardridge, W.M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. USA, 2001, 98, 12754-12759. (Pubitemid 33026054)
43. Jiang, C.; Koyabu, N.; Yonemitsu, Y.; Shimazoe, T.; Watanabe, S.; Naito, M.; Tsuruo, T.; Ohtani, H.; Sawada, Y. In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. Hum. Gene Ther., 2003, 14, 1181-1191. (Pubitemid 36930407)
44. Jiang, C.; Matsuo, H.; Koyabu, N.; Ohtani, H.; Fujimoto, H.; Yonemitsu,Y.; Kaneda, Y.; Narro, M.;, Tsuruo, T.; Sawada, Y. Transluminal gene transfer into brain capillary endothelial cells in vivo with HVJ-liposomes. J. Drug Target, 2002, 10(4), 345-352.
45. Kakinuma, K.; Tanaka, R.; Takahashi, H.; Sekihara, Y.; Watanabe, M.; Kuroki, M. Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int. J. Hyperthermia, 1996, 12, 157-165. (Pubitemid 26096974)
46. Jain, S.; Mishra, V.; Singh, P.; Dubey, P. K.; Saraf, D. K.; Vyas, S.P. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int. J. Pharm., 2003, 261, 43-55.
47. Fundaro, A.; Cavalli, R.; Bagoni, A.; Vighetto, D.; Zara, G.P.; Gasco, M.R. Non-stealth and stealth solid lipid nanoparticles (sln) carrying doxorubicin: pharmacokinetic and tissue distribution after i.v. administration to rats. Pharm. Res., 2000, 42, 337-343.
48. Reddy, J.S.; Venkateshwarlu, V. Novel delivery systems for drug targetingto the brain, Drugs Future, 2004, 29, 63-83. (Pubitemid 38252080)
49. Chen, D.; Yang, T.; Liang, W.; Zhang, Q. In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing Paclitaxel. Chem. Pharm. Bull., 2001, 49, 1444-1447. (Pubitemid 33043274)
50. Zara, G.P.; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target, 2002, 10, 327-335.
51. Manjunath, K.; Venkateshwarlu, V. Pharmacokinetics, tissue distributionand bioavalability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target, 2006, 14(9), 632-645.
52. Wang, J.X.; Sun, X.; Zhang, Z.R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm., 2002, 54(3), 285-290.
53. Gref, R.; Couvreur, P.; Barratt, G.; Mysiakine, E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials, 2003, 24, 4529-4537 (Pubitemid 36960147)
54. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81. (Pubitemid 32209233)
55. Montasser, I.; Briancon, S.; Lieto, J.; Fessi, H. Obtaining methods and formation mechanisms of polymeric nanoparticles. J. Pharm. Belg., 2000, 6, 155-167. (Pubitemid 32054879)
56. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263, 1600-1603.
57. Mosqueira, V.C.F.; Legrand, P.; Morgat, J.L.; Vert, M.; Mysiakine, E.; Gref, R. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res., 2001, 18, 1411-1419. (Pubitemid 32977246)
58. Illum, L. Chitosan and its use as a pharmaceutical excipient. Pharm Res., 1998, 15, 1326-1331.
59. Rawat, M.; Singh, S.; Saraf, S.; Saraf, S. Development and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramicnanocores for oral delivery of enzyme. Drug Dev. Ind. Pharm., 2008, 34, 181-188.
60. Ramge, P.; Unger, R.E.; Oltrogge, J.B.; Zenker, D.; Begley, D.; Kreuter, J.; Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci., 2000, 12, 1931-1940.
61. Kreuter, J.; Petrov, V.E.; Kharkevich, D.A.; Alyautdin, R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release, 1997, 49, 81-87.
62. Olivier, J.C.; Fenart, L.; Chauvet, R.; Pariat, C.; Cecchell, R.I.; Couet, W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res., 1999, 16, 1836-1842. (Pubitemid 30040699)
63. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Svetlana, E.; Gelperina.; Engelhardt, B.; Alyautdin, R.; Briesen, H.; Begley D. J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20(3), 409-416.
64. Weiss, C.K.; Kohnle, M.V.; Landfester, K.; Hauk, T.; Fischer, D.; Wienke, J.S.; Mailnder,V. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. Chem. Med. Chem., 2008, 3, 1395-1403.
65. Das. D.; Lin, S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci., 2005, 94(6), 1343-1353. (Pubitemid 40904197)
66. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.; Paramakrishnan, N.; Suresh, B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm., 2008, 70(1), 75-84.
67. Wilson, B.; Samanta, M.K.; Santhi, K.; Perumal, K.; Kumar, S.; Paramakrishnan,N.; Bhojraj, S.; .Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 2008, 1200, 159-168.
68. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A.V.; Tacchi, R.; Bertolini, A.; Vandelli, M.A.; Forni, F. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release, 2007, 122, 1-9. (Pubitemid 47284547)
69. Reimold, I.; Domke, D.; Bender, J.; Seyfried, C. A.; Radunz, H. E.; Fricker, G. Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur. J. Pharm. Biopharm., 2008, 70, 627-632.
70. Gao, X.; Wu, B.; Zhang, Q.; Chen, J.; Zhu, J.; Zhang, W.; Rong, Z.; Chen, H.; Jiang, X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Release, 2007, 121, 156-167. (Pubitemid 47212537)
71. Lu, W.; Tan, Y.Z.; Hu, K.L.; Jiang, X.G. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int. J. Pharm., 2005, 295, 247-260.
72. Kreuter, J.; Hekmatara, T.; Dreis, S.; Vogel, T.; Gelperina, S.; Langer, K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release, 2007, 118, 54-58. (Pubitemid 46283106)
73. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm., 2009, 71(2), 251-256.
74. Boche, D.; Zotova, E.; Weller, R.O.; Love, S.; Neal, J.W.; Pickering, R.M.; Wilkinson, D.; Holmes, C.; Nicoll, J.A. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131, 3299-3310.
75. Tian, J.; Shi, J.; Mann, DM. Cerebral amyloid angiopathy and dementia. Panminerva Med., 2004, 46, 253-264.
76. Tiwari, S.B.; Amiji, M.M. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv., 2006, 21, 219-232.